Systematic review and Meta-analysis of the efficacy of Apatinib and Tegafur in the treatment of colonic neoplasms

VernacularTitle:阿帕替尼和替吉奥对结肠癌治疗效果的系统评价和Meta分析
Author: Zhiyun HE ; Jie DANG ; Xiang CUI ; Zhengkui PENG ; Tianlong MA ; Jingchun FAN
From: International Journal of Surgery 2021;48(3):175-178,F4
CountryChina
Language:Chinese
Abstract: Objective:To conduct a systematic review and Meta-analysis of the efficacy and safety of Apatinib and tegafur in colonic cancer.Methods:With "Apatinib" "Tegafur" "Colonic cancer" as keywords, PubMed, Embase, Web of Science, Cochrane Library, WanFang Data, VIP, CNKI and CBM were searched from inception to December 2020 to collect randomized controlled trail about treatment for colonic cancer with Apatinib and Tegafur. Evaluated the portion remission and stable duration and progression-free survival. Meta-analysis was performed by using RevMan 5.3 software.Results:Meta-analysis showed that in colonic cancer patients, the portion remission and stable duration, tumor progression of Apatinib were not inferior to those of Tegafur ( RR=1.10, 95% CI: 0.71-1.71, P=0.640; RR=0.51, 95% CI: 0.28-1.32, P=0.205). But for progression-free survival, Apatinib was superior to Tegafur in overall patients( SMD=0.90, 95% CI: 0.42-1.37, P<0.000 1). Conclusion:In the treatment of colon cancer, compared with Tegafur, Apatinib can effectively improve the progression-free survival and has better overall survival.